<DOC>
	<DOCNO>NCT00560560</DOCNO>
	<brief_summary>This study test survival benefit patient refractory metastatic colorectal cancer receive CP-751 , 871 .</brief_summary>
	<brief_title>Study Using CP-751,871 In Patients With Stage IV Colorectal Cancer That Has Not Responded To Previous Anti-Cancer Treatments</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Patients stage IV colorectal cancer Patients whose disease worsen despite prior anticancer therapy Patients satisfactory bonemarrow , kidney liver function Patients simultaneously treat another anticancer therapy . Patients previously receive anticancer therapy work like CP751 , 871 ( target insulinlike growth factor receptor ) Patients pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Refractory Colorectal</keyword>
	<keyword>Single arm</keyword>
	<keyword>Phase 2</keyword>
</DOC>